Latest Castle Biosciences Stories
Enables physicians and patients to proactively avoid toxicities from treatments unlikely to provide benefit SAN FRANCISCO, Jan.16, 2014 /PRNewswire/ -- Castle Biosciences today announced
Castle Biosciences, a cancer diagnostics company, has signed an option agreement for a brain cancer test with the University of Texas MD Anderson Cancer Center.
Castle Biosciences, a recently formed, rapidly growing, biomarker based cancer diagnostics company, has signed an option agreement for a license agreement with The University of Texas M.D. Anderson Cancer Center.
Castle Biosciences announces the appointment of Derek Maetzold as President and CEO. Maetzold states, "It is an honor to take on this role at Castle Biosciences. We have made great progress in taking our business from plan to launch in a manner that is consistent with our vision.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.